ENTX Entera Bio Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%
Returns
ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $42,000 | $181,000 | $0 | $134,000 | $571,000 |
| Cost of revenue | $42,000 | $172,000 | $0 | $101,000 | $373,000 |
| Gross profit | $0 | $9,000 | $0 | $33,000 | $198,000 |
| R&D expense | $6.00M | $4.50M | $4.51M | $5.85M | $6.77M |
| SG&A expense | $398,000 | $340,000 | $4.43M | $7.25M | $5.69M |
| Operating income | -$11.53M | -$9.59M | -$8.89M | -$13.02M | -$12.22M |
| Pretax income | -$11.44M | -$9.53M | -$8.86M | -$12.93M | -$12.25M |
| Income tax | $0 | $14,000 | $29,000 | $137,000 | -$59,000 |
| Net income | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -$12.19M |
| EBITDA | -$11.50M | -$9.54M | -$8.84M | -$12.95M | -$12.16M |
| EPS (basic) | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 |
| EPS (diluted) | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 |
| Weighted avg. shares (diluted) | 46.19M | 37.65M | 29.01M | 28.81M | 26.13M |
| Balance sheet | |||||
| Cash & equivalents | $7.11M | $8.74M | $11.09M | $12.38M | $24.96M |
| Receivables | $0 | $126,000 | $0 | $246,000 | $183,000 |
| Current assets | $15.30M | $8.97M | $11.26M | $12.85M | $25.33M |
| PP&E, net | $134,000 | $57,000 | $100,000 | $139,000 | $156,000 |
| Total assets | $15.99M | $9.39M | $11.77M | $13.13M | $25.99M |
| Current liabilities | $2.20M | $1.18M | $1.09M | $1.34M | $3.16M |
| Total liabilities | $2.89M | $1.31M | $1.38M | $1.37M | $3.42M |
| Shareholders' equity | $13.10M | $8.08M | $10.39M | $11.75M | $22.57M |
| Shares outstanding | 46.18M | 38.84M | 35.48M | 28.81M | 28.80M |
| Cash flow statement | |||||
| Operating cash flow | -$7.37M | -$6.82M | -$7.31M | -$12.50M | -$9.06M |
| Capital expenditure | $107,000 | $3,000 | $17,000 | $47,000 | $17,000 |
| Free cash flow | -$7.48M | -$6.82M | -$7.33M | -$12.55M | -$9.08M |
| Investing cash flow | -$107,000 | -$3,000 | -$17,000 | -$102,000 | -$17,000 |
| Financing cash flow | $13.71M | $4.48M | $6.04M | $13,000 | $25.38M |
| Depreciation & amortization | $30,000 | $46,000 | $56,000 | $64,000 | $53,000 |
| Stock-based compensation | $2.75M | $2.56M | $1.69M | $2.25M | $1.86M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.